Autoimmune hepatitis - learning about your patients from their autoantibody profiles

Liver International

Volumn 32, Issue 1, 2012, Pages 5-7

  Hirschfield, Gideon M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti La; Anti Ro; Antisoluble liver antigen; Autoimmune hepatitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; HLA DR ANTIGEN; LIVER ANTIGEN; MITOCHONDRION ANTIBODY;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FAMILY HISTORY; GENETIC RISK; HIGH RISK POPULATION; HUMAN; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; FEMALE; HEPATITIS, AUTOIMMUNE; HLA-DRB1 CHAINS; HUMANS; MALE; RIBONUCLEOPROTEINS;

EID: 83255182008     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02658.x     Document Type: Editorial

References (21)

1. Decock S, Mcgee P, Hirschfield GM. Autoimmune liver disease for the non-specialist. BMJ 2009; 339: b3305.
2. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
3. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003; 1: 89-95.
4. Bhat M, Guindi M, Heathcote EJ, Hirschfield GM. Transient development of anti-mitochondrial antibodies accompanies autoimmune hepatitis-sclerosing cholangitis overlap. Gut 2009; 58: 152-3.
5. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
6. Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010; 42: 655-7.
7. Longhi MS, Hussain MJ, Kwok WW et al. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011; 53: 536-47.
8. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
9. Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-34.
10. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 379-88.
11. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer Zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-4.
12. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208-15.
13. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64.
14. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
15. Eyraud V, Chazouilleres O, Ballot E et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009; 29: 857-64.
16. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun 2010; 34: 59-65.
17. Ramos-Casals M, Sanchez-Tapias JM, Pares A, et al. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjogren's syndrome. J Rheumatol 2006; 33: 1593-9.
18. Parveen S, Morshed SA, Arima K, et al. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci 1998; 43: 1322-31.
19. Liaskos C, Bogdanos DP, Rigopoulou EL, et al. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis. J Hepatol 2007; 46(Suppl 1): S250.
20. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009; 8: 632-7.
21. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92.